Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.

Fluvoxamine significantly reduces fatigue and improves quality of life in long COVID patients, with a 99% probability of superiority over placebo at 90 days.

• Why it matters: Long COVID-related fatigue is a persistent, debilitating symptom lacking effective treatments, creating an urgent need for evidence-based therapies to improve patient outcomes.
• What they did: An adaptive, randomized, placebo-controlled trial involving 399 adults tested fluvoxamine and metformin over 60 days, measuring changes in fatigue severity and quality of life.
• The result: Fluvoxamine decreased fatigue scores by approximately 0.58 points and enhanced quality of life, suggesting its potential as a treatment, while metformin results were inconclusive due to dose-related adverse effects.